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Introduction
Systemic Antifungal therapy (SAT) of invasive candidia-
sis (IC) needs to be started immediately upon clinical
suspicion. Controversies exist then about potential
harms from antifungal de-escalation (DE).(1) In cases of
documented IC, early DE to fluconazole is recom-
mended by US guidelines but discouraged in EU guide-
lines. In non-documented IC, no data are available to
guide SAT DE. These questions are key issues however
as the relationship between antifungal use and Candida
antifungal resistance has been repeatedly demonstrated.
Objectives
To investigate whether DE within 5 days of SAT initia-
tion is associated with an increase in 28-day death in
SAT-treated non-neutropenic adult ICU patients.
Methods
Patients were recruited from AmarCAND2, a multicen-
ter prospective observational study conducted in French
ICUs (835 patients; 84 ICUs). The study included 647
non-neutropenic adult ICU patients who received SAT
for a documented or suspected invasive candidiasis and
who were alive and in the ICU after 5 days of SAT
initiation. The study considered two groups: SAT DE
group (patients switched from initial SAT to fluconazole
or to SAT stop within five days of SAT initiation) and
SAT continuation group (patient without switch or stop
of the initial SAT within five days of SAT initiation).
The average causal SAT DE effect on 28-day death was
performed by using a double robust Inverse Probability
of Treatment Weight (IPTW) estimation for observa-
tional data.
Results
Of 647 included patients, early DE at day 5 after SAT
initiation was performed in 142 patients (22%) of whom
48 (34%) SAT was stopped before day 5. The initial
SAT was mainly echinocandins (372 patients (58%)) and
fluconazole (261 patients (40%)). 276 patients (43%) had
a proven invasive candidiasis (candidemia: 41%, peritoni-
tis: 47%, deep-seated invasive Candida infection: 18%;
non-exclusive cases). Crude mortality before day 28 was
29% in the DE group, 26% in the no DE group. Main
variables associated with DE are reported on the Table
below. After adjustment on the baseline confounders,
early SAT DE was not found to be associated with
increased 28-day mortality (RR: 1.14, 95% CI [0.78-
1.66]). Results are not different if analyses are restricted
to proven IC (n = 276, RR = 0.89, 95% CI [0.53-1.49]),
suspected IC (n = 371, RR = 0.99, 95% CI [0.58-1.68]),
or first line candins therapy (n = 373, RR = 1.02, 95%
CI [0.70-1.50]). DE increased the number of day alive
without SAT (13 days [5-23] vs. 10 days [1-17] p < .01).
Figure 1.
Conclusions
In non-neutropenic adult critically ill patients with pro-
ven or suspected CI, SAT DE within 5 days was not
found to be associated with increased day-28 mortality.
Alternatively, SAT DE was found to be associated with
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decreased SAT consumption. These results show for the
first time that SAT DE is safe, more particularly in cases
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Figure 1 Main baseline difference.
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